DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W. et al.
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): A multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Lancet Oncol 2018;
19: 660-71
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.